Hostname: page-component-7c8c6479df-ws8qp Total loading time: 0 Render date: 2024-03-29T09:32:53.984Z Has data issue: false hasContentIssue false

Sodium Valproate and Tardive Dyskinesia

Published online by Cambridge University Press:  29 January 2018

Alan C. Gibson*
Affiliation:
St. Ann's Hospital, Haven Road, Canford Cliffs, Poole, Dorset BH13 7LN

Summary

Twenty-five schizophrenic patients with tardive dyskinesia were given 600 mgs sodium valproate daily with their neuroleptic medication. After one month there was no change in their signs, as judged by a panel of nine viewing films of them taken before and at the end of this treatment.

Type
Research Article
Copyright
Copyright © The Royal College of Psychiatrists 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Bordeleau, J. M., Albert, J. M. & Hillet, J. (1967) Medication antiparkinsonienne et bilan extrapyramidal: étude du trihexyphénidyl. Canadian Psychiatric Association Journal, 12, 585–94.Google Scholar
Linnoila, M., Viukari, M. & Hietala, O. (1976) Effect of sodium valproate on tardive dyskinesia. British Journal of Psychiatry, 129, 114–19.Google Scholar
Submit a response

eLetters

No eLetters have been published for this article.